Update on Tacrolimus in Patients With Interstitial Pneumonia Associated With Polymyositis or Dermatomyositis: 3-Year Postmarketing Surveillance Follow-Up in Japan.
Masataka KuwanaNaoko WakasugiTetsuji HashidaSatoshi UnoTakafumi SudaPublished in: The Journal of rheumatology (2024)
In 2013, tacrolimus was approved in Japan for the treatment of interstitial lung disease (ILD) in patients with polymyositis (PM)/dermatomyositis (DM). 1 Subsequently, Kuwana et al 2 reported the 2-year interim prospective results of a postmarketing surveillance study, which found that tacrolimus-containing immunosuppressive regimens were well tolerated in patients with PM/DM-associated ILD. 2 .
Keyphrases
- interstitial lung disease
- systemic sclerosis
- rheumatoid arthritis
- idiopathic pulmonary fibrosis
- particulate matter
- drug administration
- air pollution
- public health
- polycyclic aromatic hydrocarbons
- heavy metals
- type diabetes
- glycemic control
- disease activity
- systemic lupus erythematosus
- intensive care unit
- acute respiratory distress syndrome
- replacement therapy
- mechanical ventilation
- smoking cessation
- respiratory failure